$GNPX Resident Bear checking in with a dose of reality. Tonight is my first in a series of posts outlining Genprex's mismanagement and deceptive practices. This one should have been an obvious red flag to any investor here, but for those who missed it, let's look back at what took place back in early February of this year. Genprex released their annual shareholder letter on February 1. It was very positive regarding accomplishments from 2020 (fair enough), but the stock really took off due to 2021 being dubbed "the year of execution" with major milestones predicted for both Acclaim clinical trials. As everyone knows most of those initiatives are either way behind schedule, or have not even begun yet...
1